PRPH2-Associated Retinopathy: Novel Variants and Genotype-Phenotype Correlations.

Lorenzo Bianco, Alessandro Arrigo, Alessio Antropoli, Andrea Saladino, Ivana Spiga, Maria Grazia Patricelli, Francesco Bandello, Paola Carrera, Maurizio Battaglia Parodi

Journal: Ophthalmology. Retina 2023;7(5):450-461

PMID: 36563963

Abstract

PURPOSE

A broad spectrum of autosomal-dominant inherited retinal diseases (IRDs), ranging from mild macular pattern dystrophy to severe cone-rod degeneration, is associated with PRPH2 variants (peripherinopathies). We present detailed clinical and molecular characterization of patients affected by peripherinopathies, aiming to expand the mutational spectrum, and propose novel genotype-phenotype correlations.

DESIGN

Observational, retrospective case series.

PARTICIPANTS

Patients with an IRD related to a molecularly proven PRPH2 variant.

METHODS

Data from ophthalmic examinations and retinal imaging were collected for each follow-up visit. The standard imaging protocol included OCT, blue-light autofluorescence, near-infrared autofluorescence, and ultra-widefield fundus imaging. Genetic analysis was performed with a genomic approach by next-generation sequencing.

MAIN OUTCOME MEASURES

Results of ophthalmic examination, retinal imaging, and molecular genetic analysis.

RESULTS

Overall, a total of 19 patients with an IRD and a (likely) pathogenic PRPH2 variant were identified. Their age at presentation had a median of 48 years, whereas the symptomatic disease onset was in their 30s or 40s in 74% of cases. The median follow-up time was 4 years. Clinically, 6 patients were diagnosed with cone-rod dystrophy and 13 with pattern dystrophy. Among the 13 PRPH2 pathogenic variants identified in our cohort, 7 were missense, 3 nonsense, 2 frame shifting, and 1 splice site. Missense variants in the D2 loop were associated with cone-rod dystrophies and poor visual prognosis, whereas predicted loss-of-function alleles with pattern dystrophies and retention of a good visual function into adulthood. Overall, the following 7 variants were novel and never associated to a clinical phenotype: c.68delT, c.290G>A, c.413T>G, c.642C>G, c.702_706dupCAGTT, c.771_772delinsGA, and c.850C>G.

CONCLUSIONS

Here, we report the findings of a retrospective case series that provided a detailed clinical and molecular characterization of 19 patients harboring 13 different PRPH2 pathogenic variants, 7 of which were previously unreported, expanding the mutational spectrum of the PRPH2 gene. Loss-of-function variants might be preferentially associated with mild-pattern dystrophies, whereas missense dominant-negative variants might be preferentially associated with severely blinding cone-rod degenerations. Further studies are needed to better define the pathogenetic mechanisms and the functional effects of most variants to allow the development of successful gene therapy.

FINANCIAL DISCLOSURE(S)

Proprietary or commercial disclosure may be found after the references.

Copyright © 2022 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Address: Department of Ophthalmology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.; Department of Ophthalmology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: [email protected].; Laboratory of Clinical Genomics, IRCCS San Raffaele Scientific Institute, Milan, Italy.; Medical Genetics, IRCCS San Raffaele Scientific Institute, Milan, Italy.; Laboratory of Clinical Genomics, IRCCS San Raffaele Scientific Institute, Milan, Italy; Unit of Genomics for Human Disease Diagnosis, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Link outs

Free resources

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.